Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy.

Yu Aoki Yoshiaki Nakamura Tadamichi Denda Takashi OhtaTaito EsakiManabu ShiozawaKensei Yamaguchi Kentaro Yamazaki Yu Sunakawa Takeshi Kato Naohiro Okano Hiroya Taniguchi Taroh Satoh Eiji Oki Tomohiro NishinaYoshito KomatsuNobuhisa MatsuhashiMasahiro Goto Hisateru YasuiKoushiro OhtsuboToshikazu MoriwakiNaoki TakahashiYosuke HoritaShogen BokuMasashi WakabayashiTakashi IkenoRyuta MitaniMihoko YuasaTakayuki Yoshino

Published in: JCO precision oncology (2023)

mutations, especially with sufficient ctDNA shedding. Clinical outcomes support ctDNA genotyping for determining the use of anti-EGFR and BRAF-targeted therapies in patients with mCRC.

Keyphrases

metastatic colorectal cancer
genome wide
high throughput
circulating tumor
small cell lung cancer
epidermal growth factor receptor
genetic diversity
tyrosine kinase
wild type
dna methylation
clinical evaluation